Both of these drugs have been implicated in clinical trials and showed promising results, which caused to T-DXd drug to get FDA grant for HER2-mutant NSCLC and gastric cancer [182, 183]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.